Aim: To investigate the expression of p63 protein and ki67 antigen in a series of graded OSCC to evaluate the potential association between the expression of the two markers and the aggressiveness of histologic grades of OSCC. Methods: Hematoxylin and Eosin (H&E) and streptavidin-biotin immunoperoxidase staining techniques was used to detect the expression of p63 & ki67 in different grades of OSCC. Evaluation of immunostaining was done using computer image analyzer system & statistical analysis. Results: regarding p63 & ki67 expression were obtained by comparing the area % between different grading of OSSC, there was a statistically highly significant difference between different grades of OSCC (P<0.01) & there was a statistically significant direct correlation between p63 & ki67 stain. Conclusion: These results suggest that p63 & ki67 could reflect biological features, such as proliferation and differentiation for recognition of clinical behavior of OSCC also p63 & ki67 alteration may be associated with the progression of these neoplasms.

Aim: To study the expression of p53, PCNA & CD34 and differentiate the proliferative activity and angiogenesis of Warthin's tumor & different types of adenoid cystic carcinoma. Methods: Hematoxylin and Eosin (H&E) and immunohistochemical staining techniques were used to detect p53, PCNA & CD34 proteins in 20 cases of Warthin's tumor & different types of adenoid cystic carcinoma (solid, tubular & cribriform pattern). Evaluation of immunostaining was done using computer image analyzer system & all data were statistically analyzed. Results: There was a statistically significant difference (P<0.05) in means of expression of p53, PCNA & CD34 between Warthin's tumor & different types of adenoid cystic carcinoma. Conclusion: The expression of p53, PCNA & CD34 have been associated with aggressive tumor progression and thus has been implicated as a predictive and prognostic marker and could provide useful prognostic markers for proliferative activity and good prognostic indicators for recurrence rate of adenoid cystic carcinoma.

No abstract